|
|
|
%20LTD%20-%20484450%2015-Jan-2018_files/image007.jpg){kind=small}
%20LTD%20-%20484450%2015-Jan-2018_files/image008.jpg)
%20LTD%20-%20484450%2015-Jan-2018_files/image010.gif)
MIRA INFORM REPORT
|
Report No. : |
484450 |
|
Report Date : |
15.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
FORRESTER PHARMA (PTY) LTD |
|
|
|
|
Formerly Known As : |
AMSTINEX |
|
|
|
|
Registered Office : |
Mazars House Rialto Road, Grand Moorings Precinct Century City, 7441 |
|
|
|
|
Country : |
South Africa |
|
|
|
|
Date of Incorporation : |
27.08.2011 |
|
|
|
|
Com. Reg. No.: |
2011/107910/07 |
|
|
|
|
Legal Form : |
Private Company |
|
|
|
|
Line of Business : |
· Retail sale of pharmaceuticals ·
Wholesale of pharmaceutical goods |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
B |
|
Credit Rating |
Explanation |
Rating Comments |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
South Africa |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
SOUTH AFRICA - ECONOMIC OVERVIEW
South Africa is a middle-income emerging market with an abundant supply of natural resources; well-developed financial, legal, communications, energy, and transport sectors; and a stock exchange that is Africa’s largest and among the top 20 in the world.
Economic growth has decelerated in recent years, slowing to an estimated 0.3% in 2016. Unemployment, poverty, and inequality - among the highest in the world - remain a challenge. Official unemployment is roughly 26% of the workforce, and runs significantly higher among black youth. Even though the country's modern infrastructure supports a relatively efficient distribution of goods to major urban centers throughout the region, unstable electricity supplies retard growth. Eskom, the state-run power company, is building three new power stations and is installing new power demand management programs to improve power grid reliability; in late 2016 they issued a request for bids to revamp South Africa’s nuclear power generating capabilities. Load shedding and resulting rolling blackouts gripped many parts of South Africa in late 2014 and early 2015 because of electricity supply constraints due to technical problems at some generation units, unavoidable planned maintenance, and an accident at a power station.
South Africa's economic policy has focused on controlling inflation; however, the country faces structural constraints that also limit economic growth, such as skills shortages, declining global competitiveness, and frequent work stoppages due to strike action. The government faces growing pressure from urban constituencies to improve the delivery of basic services to low-income areas, to increase job growth, and to provide university level-education at affordable prices. Political infighting among South Africa’s ruling party and the volatility of the rand risks economic growth. International investors are concerned about the country’s long-term economic stability; as of December 2016, most major international credit ratings agencies placed South Africa only one level above junk bond status.
|
Source
: CIA |
Executive
Summary
|
Executive Summary |
Subject was unresponsive, therefore we are unable to comment on your enquiry. |
COMPANY
INFORMATION
STATUTORY INFORMATION
|
Registered Name |
FORRESTER PHARMA |
|
|
Previous Names |
AMSTINEX (11/04/2012) |
|
|
Registration Number |
2011/107910/07 |
|
|
Type Of Company |
Private Company |
|
|
Registered Date |
27/08/2011 |
|
|
Commercial Status |
In Business |
|
CONTACT DETAILS
|
Contact Number |
+27 21 943 0600 |
|
Email Address |
|
|
Fax Number |
+27 21 914 2239 |
|
Website |
|
|
Social Media Presence |
Facebook; LinkedIn; Twitter |
|
Registered Physical Address |
MAZARS HOUSE RIALTO ROAD GRAND MOORINGS PRECINCT CENTURY CITY South Africa 7441 |
|
Trading Physical Address |
13 Pasita Street; Rosen Heights Rosen Park CAPE TOWN Western Cape South Africa 7530 |
|
Postal Address |
P O Box 134 CENTURY CITY Eastern Cape South Africa 7446 |
GENERAL COMMENTS
|
Comments |
The subject was reluctant in assisting us telephonically with the required information and requested an emailed questionnaire. This was duly sent. However, to date there has been no response, despite our having followed up on numerous occasions. Any information contained in this report was obtained from outside sources and public information and is thus unconfirmed by the subject. |
TAX
INFORMATION
VAT INFORMATION
|
VAT Status |
The subject is registered for VAT (VAT number/s made available) |
|
VAT Number |
4020271047 |
|
Status |
Active |
|
Registered Name |
FORRESTER PHARMA (PTY) LTD |
OFFICERS
AND PROFESSIONAL SERVICES
LIST OF OFFICERS AND PROFESSIONAL SERVICES
|
Type |
Name |
Contact Name |
Contact Number |
|
|
Auditor |
MAZARS |
|
|
|
PRINCIPAL
INFORMATION
Director / Member
|
Full Name |
ID No. |
Type |
Status |
DOA |
Active Interests |
Previous Interests |
Judgments |
Fraud Listing |
|
CONRAD BURGER |
7605315153089 |
Director |
Active |
18/12/2014 |
11 |
0 |
0 |
0 |
|
JEROME SHELSLEY SMITH |
5409225170081 |
Director |
Active |
08/10/2013 |
12 |
16 |
0 |
0 |
|
NAZREEN GAMIELDIEN |
7609250136083 |
Director |
Active |
18/12/2014 |
10 |
3 |
0 |
0 |
|
CHRISTIAN GOUWS |
5908285147087 |
Director |
Resigned |
27/08/2011 |
0 |
0 |
0 |
0 |
|
STEPHANUS JACOBUS HENDRIKSZ |
7408255039081 |
Director |
Resigned |
24/02/2012 |
8 |
2 |
0 |
0 |
ACTIVE BUSINESS INTERESTS:
CONRAD BURGER
|
Company Name |
Registration No. |
Business Status |
Principal Status |
Principal Type |
Judgments |
|
LAMAR INTERNATIONAL |
2012/195738/07 |
In Business |
Active |
Director |
0 |
|
SHELSLEY CHEMICALS |
2012/219041/07 |
In Business |
Active |
Director |
0 |
|
UNIMARK PHARMA S.A. |
2012/218603/07 |
In Business |
Active |
Director |
0 |
|
BILLMONTNO 96 A |
2000/061224/23 |
AR Final deregistration |
Active |
Member |
0 |
|
MAZARS |
2005/025794/21 |
In Business |
Active |
Director |
0 |
|
GENEROFARMA |
2014/214938/07 |
In Business |
Active |
Director |
0 |
|
SERUM INSTITUTE OF INDIA SA |
2014/118223/07 |
In Business |
Active |
Director |
0 |
|
WHYENBAH |
2014/273758/07 |
AR Deregistration Process |
Active |
Director |
0 |
|
FOX PHARMA |
2012/145125/07 |
In Business |
Active |
Director |
0 |
|
EXELTIS SOUTH AFRICA |
2013/006996/07 |
In Business |
Active |
Director |
0 |
|
EYEPHARMA |
2014/214271/07 |
In Business |
Active |
Director |
0 |
ACTIVE BUSINESS INTERESTS:
JEROME SHELSLEY SMITH
|
Company Name |
Registration No. |
Business Status |
Principal Status |
Principal Type |
Judgments |
|
IPC INTERNATIONAL |
2014/075647/07 |
In Business |
Active |
Director |
0 |
|
CAVALLI WINE AND STUD |
2013/006902/07 |
In Business |
Active |
Director |
0 |
|
L'AMAR (FRANCE) PHARMATEC |
2007/009915/07 |
In Business |
Active |
Director |
0 |
|
ZUID INVESTMENTS |
2006/035530/07 |
In Business |
Active |
Director |
0 |
|
SERUM INSTITUTE OF INDIA SA |
2014/118223/07 |
In Business |
Active |
Director |
0 |
|
UNIMARK PHARMA S.A. |
2012/218603/07 |
In Business |
Active |
Director |
0 |
|
GENEROFARMA |
2014/214938/07 |
In Business |
Active |
Director |
0 |
|
IPC GLOBAL |
2014/075650/07 |
In Business |
Active |
Director |
0 |
|
SHELSLEY CHEMICALS |
2012/219041/07 |
In Business |
Active |
Director |
0 |
|
LAMAR INTERNATIONAL |
2012/195738/07 |
In Business |
Active |
Director |
0 |
|
EYEPHARMA |
2014/214271/07 |
In Business |
Active |
Director |
0 |
|
EXELTIS SOUTH AFRICA |
2013/006996/07 |
In Business |
Active |
Director |
0 |
PREVIOUS BUSINESS
INTERESTS: JEROME SHELSLEY SMITH
|
Company Name |
Registration No. |
Business Status |
Principal Status |
Principal Type |
Judgments |
|
SMITH AND COUZIN |
2002/025723/07 |
Deregistration Final |
Resigned |
Director |
0 |
|
FOX PHARMA |
2012/145125/07 |
In Business |
Resigned |
Director |
0 |
|
ASCENDIS ANIMAL HEALTH |
2004/021847/07 |
In Business |
Resigned |
Director |
0 |
|
CASTLE AG-CHEM |
2007/033120/07 |
In Business |
Resigned |
Director |
0 |
|
MEDPRO-ON-LINE |
2002/025721/07 |
Deregistration Final |
Resigned |
Director |
0 |
|
CONSUMPTION BEVERAGES |
2005/041320/07 |
In Business |
Resigned |
Director |
0 |
|
CIPLA PERSONAL CARE |
2001/008573/07 |
Deregistration Final |
Resigned |
Director |
0 |
|
ASCENDIS VET |
2001/017471/07 |
In Business |
Resigned |
Director |
0 |
|
CIPLA MEDPRO CARDIO RESPIRATORY |
2004/001451/07 |
Deregistration Final |
Resigned |
Director |
0 |
|
CIPLA MEDPRO ARV |
2003/008790/07 |
Deregistration Final |
Resigned |
Director |
0 |
|
CIPLA MEDPRO HOLDINGS |
2000/018468/07 |
In Business |
Resigned |
Director |
0 |
|
CIPLA HEALTH CARE |
2000/001463/07 |
Deregistration Final |
Resigned |
Director |
0 |
|
CIPLA DIBCARE |
2005/029296/07 |
Voluntary Liquidation |
Resigned |
Director |
0 |
|
CIPLA LIFE SCIENCES |
2000/001167/07 |
In Business |
Resigned |
Director |
0 |
|
MEDPRO PHARMACEUTICA |
1992/000182/07 |
In Business |
Resigned |
Director |
0 |
|
MEDPRO PHARMACEUTICA AFRICA |
2008/023062/07 |
Deregistration Final |
Resigned |
Director |
0 |
ACTIVE BUSINESS
INTERESTS: NAZREEN GAMIELDIEN
|
Company Name |
Registration No. |
Business Status |
Principal Status |
Principal Type |
Judgments |
|
GENEROFARMA |
2014/214938/07 |
In Business |
Active |
Director |
0 |
|
IPC GLOBAL |
2014/075650/07 |
In Business |
Active |
Director |
0 |
|
LEBASI PHARMA |
1998/064179/23 |
In Business |
Active |
Member |
0 |
|
EXELTIS SOUTH AFRICA |
2013/006996/07 |
In Business |
Active |
Director |
0 |
|
FOX PHARMA |
2012/145125/07 |
In Business |
Active |
Director |
0 |
|
SERUM INSTITUTE OF INDIA SA |
2014/118223/07 |
In Business |
Active |
Director |
0 |
|
LAMAR INTERNATIONAL |
2012/195738/07 |
In Business |
Active |
Director |
0 |
|
LIONESS HOLDINGS |
2013/228540/07 |
In Business |
Active |
Director |
0 |
|
EYEPHARMA |
2014/214271/07 |
In Business |
Active |
Director |
0 |
|
IPC INTERNATIONAL |
2014/075647/07 |
In Business |
Active |
Director |
0 |
PREVIOUS BUSINESS
INTERESTS: NAZREEN GAMIELDIEN
|
Company Name |
Registration No. |
Business Status |
Principal Status |
Principal Type |
Judgments |
|
CIPLA-MEDPRO |
1995/004182/07 |
In Business |
Resigned |
Director |
0 |
|
MEDPRO PHARMACEUTICA |
1992/000182/07 |
In Business |
Resigned |
Director |
0 |
|
CIPLA LIFE SCIENCES |
2000/001167/07 |
In Business |
Resigned |
Director |
0 |
Management
No principals found for this principal type.
Officer
No principals found for this principal type.
Other
No principals found for this principal type
OPERATIONAL
ACTIVITIES
|
Operational Activities Status |
The following information was provided |
|
|
Industry |
Retail |
|
|
Major Industry SIC Code |
47620 - Retail sale of pharmaceuticals |
|
|
NACE Code |
46,46 - Wholesale of pharmaceutical goods |
|
MAJOR OPERATION
|
Major Business Activities |
Subject is involved in providing healthcare products. |
|
|
Foreign Trade Activities |
National |
|
|
Agencies Held |
Subject holds no agencies. |
|
|
Franchises Held |
The subject holds no franchises. |
|
|
Major Suppliers |
LAMAR |
|
|
Major Customers |
Healthcare Industry General Public |
|
|
Major Brands |
· ELEVATION CONDOMS · SINUFIX FORTE · HYDROMIST · SENTRY C · DRI-GON · SENTRY M · IVYFILM · TRUBIOTIC |
|
|
Major Contracts |
Subject does not operate on a contract basis. |
|
COURT
NOTICES
COMPANY JUDGMENTS
|
Case Number |
Judgment Date |
Judgment Type |
Amount |
Court Name |
Plaintiff |
Defendants |
|
|
12184 |
18/02/2015 |
VAT |
667,758 |
NORTH GAUTENG HIGH COURT |
SARS |
FORRESTER PHARMA (PTY) LTD |
|
No liquidation applications on file in the name of the subject
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.53 |
|
|
1 |
INR 86.05 |
|
Euro |
1 |
INR 76.53 |
|
ZAR |
1 |
INR 5.13 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
NIY |
|
|
|
|
Report Prepared
by : |
KET |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with moderate
risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on secured
terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.